Celcuity Inc. (CELC)
NASDAQ: CELC · Real-Time Price · USD
104.51
-0.36 (-0.34%)
At close: Feb 13, 2026, 4:00 PM EST
106.91
+2.40 (2.30%)
After-hours: Feb 13, 2026, 7:53 PM EST
Celcuity Employees
Celcuity had 87 employees as of December 31, 2024. The number of employees increased by 32 or 58.18% compared to the previous year.
Employees
87
Change (1Y)
32
Growth (1Y)
58.18%
Revenue / Employee
n/a
Profits / Employee
-$1,870,369
Market Cap
4.84B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 87 | 32 | 58.18% |
| Dec 31, 2023 | 55 | 10 | 22.22% |
| Dec 31, 2022 | 45 | 6 | 15.38% |
| Dec 31, 2021 | 39 | 9 | 30.00% |
| Dec 31, 2020 | 30 | 3 | 11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Corcept Therapeutics | 500 |
| Amicus Therapeutics | 499 |
| Crinetics Pharmaceuticals | 437 |
| CRISPR Therapeutics AG | 393 |
| TG Therapeutics | 374 |
| Immunovant | 362 |
| Structure Therapeutics | 218 |
| Apogee Therapeutics | 196 |
CELC News
- 22 hours ago - Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha
- 1 day ago - Celcuity Appoints Charles Romp to its Board of Directors - GlobeNewsWire
- 10 days ago - Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 23 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 25 days ago - Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - GlobeNewsWire
- 7 weeks ago - Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond - Seeking Alpha
- 2 months ago - Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Celcuity: From Speculative Bet To Pre-Commercial Powerhouse - Seeking Alpha